A peer-reviewed version of this preprint was published in PeerJ on 12 March 2015.

View the peer-reviewed version (peerj.com/articles/813), which is the preferred citable publication unless you specifically need to cite this preprint.

Zhao M, Li X, Li M, Gao Y. (2015) Effects of anesthetics pentobarbital sodium and chloral hydrate on urine proteome. PeerJ 3:e813
https://doi.org/10.7717/peerj.813
Title

Effects of Anesthetics Pentobarbital Sodium and Chlora Hydrate on Urine Proteome

Authors: Mindi Zhao§ and Youhe Gao¶*  

* Corresponding author Email: gaoyouhe@bnu.edu.cn

Affiliations:
§Department of Biochemistry and Molecular Biology, Beijing Normal University, Gene Engineering and Biotechnology Beijing Key Laboratory, Beijing, China
¶National Key Laboratory of Medical Molecular Biology, Department of Pathophysiology, Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences, School of Basic Medicine, Peking Union Medical College, Beijing, China

Tel and Fax: 86-10-58804382
Abstract

Background. Urine can be a better source than blood for biomarker discovery since it accumulates many changes. The urine proteome is susceptible to many factors including anesthesia. Pentobarbital sodium and chloral hydrate are commonly used anesthetics in animal experiments.

Methods. This study demonstrated effects of these two anesthetics on the rat urine proteome using liquid chromatography–tandem mass spectrometry (LC-MS/MS).

Results. With anesthesia, the urinary protein-to-creatinine ratio of all rats increased two fold. The relative abundance of 22 and 23 urinary proteins were changed with pentobarbital sodium or chloral hydrate anesthesia, respectively, as determined by label-free quantification. Among these changed proteins, fifteen had been considered as candidate biomarkers such as uromodulin, sixteen had been considered stable in healthy human urine, which are more likely to be considered as potential biomarkers when changed, such as transferrin.

Discussion. The pattern of changed urinary proteins provides clues to the discovery of urinary proteins regulatory mechanisms. When determining candidate biomarker, anesthetic-related effects can be excluded in future biomarker discovery studies. Since anesthetics take effects via nervous system, this study is the first to provide clues that protein handling function of kidney may possibly be regulated by nervous system.

Keywords: Urine proteome; Anesthesia; Biomarkers
Introduction

Change is the most fundamental characteristic of biomarker. Urine can be a better non-invasive source for biomarker discovery since it accumulates many changes (Gao 2013). Changes introduced into the blood can be more sensitively detected in urine (Li et al. 2014a). As summarized in a recent paper (Gao 2014b), in some previous biomarker studies, several potential biomarkers perform even better in urine than in blood (Huang et al. 2012; Payne et al. 2009; Wu et al. 2013). Urine proteome is affected by many factors, such as age, gender, lifestyle and others. As a result, despite the advantage of urine as a better biomarker source, urine biomarker research can be difficult as changes in urine are much too complex to sort out factors associated directly with any particular condition, especially in human samples (Gao 2013). Minimizing the confounding factors by using animal model was illustrated in renal disease animal models (Gao 2014c; Zhao et al. 2014). In fact, the number of factors that can affect the urine proteome is still unknown, a better understanding of those factors’ effects on urine proteome help to speed up biomarkers discovery. It has been proposed that only changes of stable components in urine proteome are more likely to become biomarkers (Sun et al. 2009). Other physiological factors such as water loading, sodium loading, cigarette smoking, diuretics and anticoagulants were found to change urine proteome too (Airoldi et al. 2009; Li et al. 2014b; Thongboonkerd et al. 2003).

Also changes caused by medications usually neglected when clinical experiments were designed. The patients-medicine, healthy-no medicine associations exist in all of clinical biomarker studies. So “pharmuromics”, which studies the effects of medicine on urine, was purposed (Gao 2014a). Anesthetist is commonly used in animal experiments, as well as surgery. However, the effects of anesthetics on urine proteome are not usually considered.
It is not clear whether anesthesia affects the urine proteome. In this study, effects of pentobarbital sodium and chloral hydrate anesthesia on the rat urine proteome were studied using liquid chromatography–tandem mass spectrometry (LC-MS/MS).

**Materials and methods**

**Experiment animals**

Rats were purchased from the Institute of Laboratory Animal Science, Chinese Academy of Medical Science & Peking Union Medical College. The experiment was approved by Institute of Basic Medical Sciences Animal Ethics Committee, Peking Union Medical College (Animal Welfare Assurance Number: ACUC-A02-2013-015). All animals were kept with standard laboratory diet under controlled indoor temperature (22 ± 1 ºC) and humidity (65 – 70 %). The study was performed according to guidelines developed by Institutional Animal Care and Use Committee of Peking Union Medical College.

**Rat models**

Twelve male Sprague-Dawley rats (weight = 200 g) were divided into two groups. One group was anesthetized by intraperitoneal injection of pentobarbital sodium (n = 6, 50 mg/kg), and the other group was by chloral hydrate (n = 6, 300 mg/kg). Urine samples before anesthesia were collected as control. Anesthesia affected urine was collected during anesthesia. The activities of the anesthetics were detected by measuring muscle relaxation. The self-controlled experiment was conducted in two phases: for the discovery phase, differential protein identification was performed in three independent rats each group; for the validation phase, samples were obtained from the three remaining rats.

**Sample preparation**

Urine was centrifuged at 2000 g for 30 min immediately after collection. Three volumes
of acetone were added after removing the pellets and precipitated at 4 °C. Then, lysis buffer
(8 M urea, 2 M thiourea, 25 mM dithiothreitol and 50 mM Tris) was used to re-dissolve
the pellets. Proteins were digested by trypsin (Trypsin Gold, Mass Spec Grade, Promega,
Fitchburg, Wisconsin) using filter-aided sample preparation methods (Wisniewski et al.
2009). Briefly, after proteins were loaded on the filter unit (Pall, Port Washington, New
York, USA), UA buffer (8 M urea in 0.1 M Tris–HCl, pH 8.5) and 50 mM NH₄HCO₃ was
added. Proteins were denatured at 50 ºC for 1 h by the addition of 20 mM dithiothreitol and
alkylated in the dark for 40 min by the addition of 50 mM iodoacetamide. Proteins were
digested by trypsin (1:50) at 37 ºC overnight. The digested peptides were desalted using
Oasis HLB cartridges (Waters, Milford, MA).

**LC-MS/MS analysis**

The digested peptides were dissolved in 0.1 % formic acid and loaded on a Michrom
Peptide Captrap column (MW 0.5 – 50 kD, 0.5 × 2 mm; MichromBioresources). The eluent
was transferred to a reversed-phase microcapillary column (0.1 × 150 mm, packed with
Magic C18, 3 μm, 200 Å; MichromBioresources) by an Agilent 1200 HPLC system.
Peptides were analyzed by a LTQ-OrbitrapVelos mass spectrometer (Thermo Fisher
Scientific, Bremen, Germany). The LTQ-OrbitrapVelos was operated in data-dependent
acquisition mode. Survey MS scans were acquired in the Orbitrap using a 300 - 2000 m/z
range with the resolution set to 60,000. The 20 most intense ions per survey scan were
selected for CID fragmentation, and the resulting fragments were analyzed in the LTQ.
Dynamic exclusion was employed with a 60 sec window to prevent the repetitive selection
of the same peptide.

**Data analysis**
All MS/MS spectra were analyzed using the Mascot search engine (version 2.4.1, Matrix Science, London, UK), and proteins were identified by searching against the Swissprot_2013_07 database (taxonomy: Rattus; containing 9354 sequences). The parameters were set as follows: carbamidomethylation of cysteines was set as a fixed modification, and oxidation of methionine and protein N-terminal acetylation were set as variable modifications. Trypsin was set as the digestion enzyme, and two missed trypsin cleavage sites were allowed. The precursor mass tolerance was set to 10 ppm, and the fragment mass tolerance was set to 0.5 Da. Peptide and protein identifications were validated by Scaffold (version 4.0.1, Proteome Software Inc., Portland, OR). Peptide identifications were accepted if they could be detected with ≥ 95.0% probability by the Scaffold local FDR algorithm, and protein identifications were accepted if they could be detected with ≥ 99.0% probability and contained at least 2 identified peptides (Nesvizhskii et al. 2003). The acquired raw files were loaded to Progenesis LC-MS/MS software (version 4.1, Nonlinear, Newcastle upon Tyne, UK), and label-free quantification was conducted as previously described (Hauck et al. 2010). For quantification, all peptides (with Mascot score>30 and p<0.01) of an identified protein were included.

**Western blot analysis**

Urine proteins were prepared as described in materials and methods, 20ug of each sample were separated by 10% SDS-PAGE and transferred to PVDF membranes (Whatman, Maidstone, UK) in transfer buffer (10% methanol, 25mM Tris base, 192mM glycine, PH 8.0). Membranes were incubated overnight at 4 °C with primary antibody against alpha-1-antiproteinase (dilution 1:1000; ab106582, Abcam, Cambridge, UK) or transferrin (dilution 1:10000; ab82411, Abcam, Cambridge, UK). The membranes were then washed
and incubated with peroxidase-conjugated IgG and proteins were visualized using enhanced chemiluminescence (ECL) reagents. Intensity of each protein band was quantified using Image J analysis software (National Institutes of Health, Bethesda, Maryland, USA).

Results

**Urine protein-to-creatinine ratios were increased with either pentobarbital sodium or chloral hydrate anesthesia**

When compared with normal urine, the urine protein-to-creatinine values with anesthesia increased 2.4-fold (in pentobarbital sodium group, 107.1 ± 21.1 vs. 259.1 ±81.1 mg/mmol, n=6, P value < 0.05) and 2.1-fold (in chloral hydrate group, 107.5 ± 16.5 vs. 220.8 ±79.0 mg/mmol, n=6, P value <0.05). With pentobarbital sodium and chloral hydrate anesthesia, the urine protein-to-creatinine ratio of all rats were significantly increased in both groups, which were consistent with the values that have been reported in previous studies (Mercatello A 1991; Vaden et al. 2010). Figure 1 showed the different effects of each anesthetic on rat urine protein concentration.

**Urinary proteome changes with anesthesia**

Twelve urine samples before and after anesthesia from 6 rats (n=3 in each group) in the pentobarbital sodium and chloral hydrate group were individually identified by LC-MS/MS. In the pentobarbital sodium and chloral hydrate group, label-free quantitation data of proteins identified were listed in the Additional file 1.

In the pentobarbital sodium group, the relative abundance of 22 proteins changed according to the following criteria: fold change > 2 for each rat and p value <0.05; 6 proteins had increased relative abundance and 16 proteins had decreased relative
abundance. In the chloral hydrate group, the relative abundance of 23 proteins changed: 9 proteins had increased relative abundance and 14 proteins had decreased relative abundance. Among the proteins with altered relative abundance, 7 had the same trends in all six rats that were anesthetized with either pentobarbital sodium or chloral hydrate; one protein increased relative abundance and six proteins had decreased relative abundance (Table 1).

**Verification of affected proteins by Western blot**

Two changed proteins were selected to be validated in six more rats for the following reasons: (1) were identified previously in biomarker discovery; (2) were at relatively high abundance and easier to be detected in western blot; (3) had commercially available antibodies. In the pentobarbital sodium group, the levels of transferrin were analyzed and in the chloral hydrate group, the levels of alpha-1-antiproteinase were analyzed. With anesthesia, transferrin and alpha-1-antiproteinase expression levels were upregulated in three more rats (Figure 2), consistent with the MS quantification data.

**Comparison with previous studies**

In the pentobarbital sodium anesthesia group, the relative abundance of 22 proteins were changed. Compared with the Urinary Protein Biomarkers Database (Shao et al. 2011), 11 out of 22 proteins were considered as candidate biomarkers, such as uromodulin and serotransferrin. Among these proteins, some exhibited the opposite trend. For example, the relative abundance of aminopeptidase N was increased in septic rats with acute renal failure (Wang et al. 2008), whereas their relative abundance decreased with pentobarbital sodium anesthesia. In the chloral hydrate anesthesia group, the relative abundance of 23 proteins changed and chloral hydrate had a relatively different impact on the urine
proteome. Compared with the Urinary Protein Biomarkers Database, 8 out of 23 proteins were considered as candidate biomarkers, such as uromodulin and parvalbumin alpha. However, the relative abundance of clusterin was increased under conditions of gentamicin administration (Takahashi 1995), but it decreased with chloral hydrate anesthesia.

Rat proteins were converted to their human orthologs using Ensembl homolog database as reported (Jia et al. 2013). For stable proteins in the healthy human urine, when changed, are more likely to become candidate biomarkers (Sun et al. 2009). So differently expressed proteins with anesthesia in this study were used to compare with the human core urinary proteome which were considered relatively high abundant and stable. Data from the “stable urinary proteome”, which represented the common and most easily identifiable proteins from urine, were determined by Mann (Nagaraj & Mann 2011). The dataset contains 587 proteins that were identified in each of the 7 participant’s urinary proteomes on three consecutive days. The changes of high abundant proteins are likely to be real, as it is unlikely to be caused by data dependent sampling of low abundant peptides by MS. 6 out of 22 proteins (Uromodulin, Kallikrein-1, Serotransferrin, Serum albumin, Gamma-glutamyl hydrolase, Neutral and basic amino acid transport protein rBAT) affected by pentobarbital sodium had stable relative abundance in healthy human urine. 10 out of 23 proteins (Uromodulin, Kallikrein-1, Superoxide dismutase [Cu-Zn], Putative uncharacterized protein, Parvalbumin alpha, Corticosteroid-binding globulin, E-cadherin, Alpha/beta hydrolase domain-containing protein 14B, Retinoid-inducible serine carboxypeptidase, Apolipoprotein E) affected by chloral hydrate were stable. Two proteins (Uromodulin, Kallikrein-1) were shared by both groups (Table 2 listed the changed proteins which exist in human core urinary proteins).
Discussion

Two validated changing proteins, transferrin and the alpha-1-antiproteinase, are two of most common markers of renal diseases. Transferrin is a plasma protein that transports iron through different tissues and organs (Crichton & Charloteaux-Wauters 1987). The blood transferrin is used to determine the cause of anemia and examine iron metabolism. Urinary transferrin is upregulated in many diseases such as diabetic nephropathy, IgA nephropathy, ureteropelvic junction obstruction and bladder cancer (Shao et al. 2011). Alpha-1-antiproteinase can inhibit many proteases thus protects tissues from enzymes of inflammatory cells (Wu & Foreman 1991). Alpha-1-antiproteinase is also upregulated in many diseases such as kidney calculi, nephrotic syndrome, bladder cancer and focal segmental glomerulosclerosis (Shao et al. 2011). As these two candidate biomarkers are affected by anesthetics pentobarbital sodium or chloral hydrate, it is necessary to exclude anesthetic-related effects in future biomarker discovery studies.

Seven changed proteins shared the same trend in both groups, which could be explained by the common mechanisms of action of two general anesthetics. Pentobarbital sodium at anesthetic dose inhibits Ca^{2+}-dependent release of neurotransmitters and increases the duration of Cl$^-$ channel opening at the GABA_A receptor (Orser et al. 1998; Pistis et al. 1999). Chloral hydrate also potentiates GABA-activated Cl$^-$ current in central nervous system neurons by its main active metabolite trichloroethanol (Peoples & Weight 1994). The common effects of these two anesthetics on urine proteome suggested the nervous system is possibly involved in regulation of urinary proteins. But exactly how these two anesthetics affect urinary proteins remains unknown. It may include direct and/or indirect effects.
Central GABA receptor stimulation reduces renal sympathetic nerve discharge (Antonaccio & Taylor 1977), which induce vasodilatation, especially in the arcuate and interlobular arteries (Kirchheim et al. 1987). Central administration of GABA agonists reduce blood pressure and heart rate (Antonaccio et al. 1978), which could affect renal blood flow, glomerular filtration rate, renal tubular reabsorption rate (Holstein-Rathlou et al. 1982; Mercatello 1990) and possibly urinary proteins.

It was proposed that GABA antagonize the central effects of renin (Abe et al. 1988). The less release of renin may consequently affect the renal sodium metabolism (Zacchia & Capasso 2008), which may explain why Na (+)/H (+) exchange regulatory cofactor and parvalbumin (a key protein in early distal tubule Na+ reabsorption) were affected with chloral hydrate anesthesia.

The fact that changed proteins with pentobarbital sodium and chloral hydrate anesthesia were not all the same, suggested that two anesthetics might have differences in the modes of action. Chloral hydrate also targets on 5-HT3 receptor (Bentley & Barnes 1998), which may help to explain the different effects of the two anesthetics. Previous study also showed that pentobarbital sodium anesthesia may influence hematologic values such as clotting time and partial thromboplastin time (Gentry & Black 1976), which may explain why kallikrein-1 and urokinase-type plasminogen activator changes with pentobarbital sodium anesthesia.

Analysis above suggests that urinary proteins may be able to reflect the functional changes as far as central nerve system. A better understanding of this mechanism will help to understand renal physiology, pathophysiology and the relationship between biomarkers and related diseases.
Acknowledgements

This work was supported by the National Basic Research Program of China (2012CB517606, 2013CB530805, 2014CBA02005 and 2013FY114100), Expertise-Introduction Project for Disciplinary Innovation of Universities (B08007).

References

Abe M, Tokunaga T, Yamada K, and Furukawa T. 1988. Gamma-aminobutyric acid and taurine antagonize the central effects of angiotensin II and renin on the intake of water and salt, and on blood pressure in rats. *Neuropharmacology* 27:309-318.

Airoldi L, Magagnotti C, Iannuzzi AR, Marelli C, Bagnati R, Pastorelli R, Colombi A, Santaguida S, Chiabrando C, Schiarea S, and Fanelli R. 2009. Effects of cigarette smoking on the human urinary proteome. *Biochem Biophys Res Commun* 381:397-402.

Antonaccio MJ, Kerwin L, and Taylor DG. 1978. Reductions in blood pressure, heart rate and renal sympathetic nerve discharge in cats after the central administration of muscimol, a GABA agonist. *Neuropharmacology* 17:783-791.

Antonaccio MJ, and Taylor DG. 1977. Involvement of central GABA receptors in the regulation of blood pressure and heart rate of anesthetized cats. *Eur J Pharmacol* 46:283-287.

Bentley KR, and Barnes NM. 1998. 5-hydroxytryptamine3 (5-HT3) receptor-mediated depolarisation of the rat isolated vagus nerve: modulation by trichloroethanol and related alcohols. *Eur J Pharmacol* 354:25-31.

Crichton RR, and Charleux-Wauters M. 1987. Iron transport and storage. *Eur J Biochem* 164:485-506.

Curtis P, Evens S, Resnick J, Thompson CJ, Rimer R, and Hisley J. 1989. Patterns of uterine contractions and prolonged uterine activity using three methods of breast stimulation for contraction stress tests. *Obstet Gynecol* 73:631-638.

Cutillas PR, Chalkley RJ, Hansen KC, Cramer R, Norden AG, Waterfield MD, Burlingame AL, and Unwin RJ. 2004. The urinary proteome in Fanconi syndrome implies specificity in the reabsorption of proteins by renal proximal tubule cells. *Am J Physiol Renal Physiol* 287:F353-364.

Dare TO, Davies HA, Turton JA, Lomas L, Williams TC, and York MJ. 2002. Application of surface-enhanced laser desorption/ionization technology to the detection and identification of urinary parvalbumin-alpha: a biomarker of compound-induced skeletal muscle toxicity in the rat. *Electrophoresis* 23:3241-3251.

Gao Y. 2013. Urine—an untapped goldmine for biomarker discovery? *Sci China Life Sci* 56:1145-1146.

Gao Y. 2014a. Are Urinary Biomarkers from Clinical Studies Biomarkers of Disease or Biomarkers of Medicine? *MOJ Proteomics Bioinformatics* 1:00028.

Gao Y. 2014b. Opportunities You Do Not Want to Miss and Risks You Cannot Afford to Take in Urine Biomarker Era. *MOJ Proteomics Bioinformatics* 1:00003.

Gao Y. 2014c. Roadmap to the Urine Biomarker Era. *MOJ Proteomics Bioinformatics* 1:00005.

Gentry PA, and Black WD. 1976. Influence of pentobarbital sodium anesthesia on hematologic values in the dog. *Am J Vet Res* 37:1349-1352.

Hauck SM, Dieter J, Kramer RL, Hofmaier F, Zipples JK, Amann B, Feuchtinger A, Deeg CA, and Ueffing M. 2010. Deciphering membrane-associated molecular processes in target tissue of autoimmune uveitis by label-free quantitative mass spectrometry. *Mol Cell Proteomics* 9:2292-2305.

Holstein-Rathlou NH, Christensen P, and Leyssac PC. 1982. Effects of halothane-nitrous oxide inhalation anesthesia and Inacitin on overall renal and tubular function in Sprague-Dawley and Wistar rats. *Acta Physiol Scand* 114:193-201.

Huang JT, Chaudhuri R, Albarbarawi O, Barton A, Grierson C, Rauchhaus P, Weir CJ, Messow M, Stevens N, and McSharry C. 2012. Clinical validity of plasma and urinary desmosine as biomarkers for chronic...
obstructive pulmonary disease. *Thorax* 67:502-508.

Jia L, Li X, Shao C, Wei L, Li M, Guo Z, Liu Z, and Gao Y. 2013. Using an Isolated Rat Kidney Model to Identify Kidney Origin Proteins in Urine. *PLoS One* 8:e66911.

Jiang H, Guan G, Zhang R, Liu G, Cheng J, Hou X, and Cui Y. 2009. Identification of urinary soluble E-cadherin as a novel biomarker for diabetic nephropathy. *Diabetes Metab Res Rev* 25:232-241.

Kirchheim HR, Ehmke H, Hackenthal E, Lowe W, and Persson P. 1987. Autoregulation of renal blood flow, glomerular filtration rate and renin release in conscious dogs. *Pflugers Arch* 410:441-449.

Li M, Zhao M, and Gao Y. 2014a. Changes of proteins induced by anticoagulants can be more sensitively detected in urine than in plasma. *Sci China Life Sci* 57:649-656.

Li X, Zhao M, Li M, Jia L, and Gao Y. 2014b. Effects of Three Commonly-used Diuretics on the Urinary Proteome. *Genomics, proteomics & bioinformatics*.

Linden M, Lind SB, Mayrhofer C, Segersten U, Wester K, Lytvinskiy Y, Zubarev R, Malmstrom PU, and Pettersson U. 2012. Proteomic analysis of urinary biomarker candidates for nonmuscle invasive bladder cancer. *Proteomics* 12:135-144.

Malard V, Gaillard JC, Berenguer F, Sage N, and Quemeneur E. 2009. Urine proteomic profiling of uranium nephrotoxicity. *Biochim Biophys Acta* 1794:882-891.

Mercatello A. 1990. Changes in renal function induced by anesthesia. *Ann Fr Anesth Reanim* 9:507-524.

Mercatello A H-AA, Chery C, Sagnard P, Pozet N, Tissot E, Boulez J, Moskovtchenko JF. 1991. Microalbuminuria is acutely increased during anesthesia and surgery. *Nephron* 58:161-163.

Nagaraj N, and Mann M. 2011. Quantitative analysis of the intra- and inter-individual variability of the normal urinary proteome. *J Proteome Res* 10:637-645.

Narita T, Sasaki H, Hosoba M, Miura T, Yoshioka N, Morii T, Shimotomai T, Koshimura J, Fujita H, Kakei M, and Ito S. 2004. Parallel increase in urinary excretion rates of immunoglobulin G, ceruloplasmin, transferrin, and orosomucoid in normoalbuminuric type 2 diabetic patients. *Diabetes Care* 27:1176-1181.

Nesvizhskii AI, Keller A, Kolker E, and Aebersold R. 2003. A statistical model for identifying proteins by tandem mass spectrometry. *Anal Chem* 75:4646-4658.

Nordberg GF, Jin T, Hong F, Zhang A, Buchet JP, and Bernard A. 2005. Biomarkers of cadmium and arsenic interactions. *Toxicol Appl Pharmacol* 206:191-197.

Orser BA, McAdam LC, Roder S, and MacDonald JF. 1998. General anaesthetics and their effects on GABA(A) receptor desensitization. *Toxicol Lett* 100-101:217-224.

Payne SR, Serth J, Schostak M, Kamradt J, Strauss A, Thelen P, Model F, Day JK, Liebenberg V, and Morotti A. 2009. DNA methylation biomarkers of prostate cancer: Confirmation of candidates and evidence that the body is the most sensitive fluid for non-invasive detection. *The Prostate* 69:1257-1269.

Peoples RW, and Weight FF. 1994. Trichloroethanol potentiation of gamma-aminobutyric acid-activated chloride current in mouse hippocampal neurones. *Br J Pharmacol* 113:555-563.

Pistis M, Belelli D, McGurk K, Peters JA, and Lambert JJ. 1999. Complementary regulation of anaesthetic activation of human (alpha6beta3gamma2L) and Drosophila (RDL) GABA receptors by a single amino acid residue. *J Physiol* 515 (Pt 1):3-18.

Shao C, Li M, Li X, Wei L, Zhu L, Yang F, Jia L, Mu Y, Wang J, Guo Z, Zhang D, Yin J, Wang Z, Sun W, Zhang Z, and Gao Y. 2011. A tool for biomarker discovery in the urinary proteome: a manually curated human and animal urine protein biomarker database. *Mol Cell Proteomics* 10:M111 010975.

Sun W, Chen Y, Li F, Zhang L, Yang R, Zhang Z, Zheng D, and Gao Y. 2009. Dynamic urinary proteome analysis reveals stable proteins to be potential biomarkers. *Proteomics - Clinical Applications* 3:370-382.

Takahashi M. 1995. Increased urinary fibronectin excretion in type II diabetic patients with microalbuminuria. *Nihon Jinzo Gakkai Shi* 37:336-342.

Thongboonkerd V, Klein JB, Pierce WM, Jevans AW, and Arthur JM. 2003. Sodium loading changes urinary protein excretion: a proteomic analysis. *Am J Physiol Renal Physiol* 284:F1155-1163.

Vaden SL, Turman CA, Harris TL, and Marks SL. 2010. The prevalence of albuminuria in dogs and cats in an ICU or recovering from anesthesia. *J Vet Emerg Crit Care (San Antonio)* 20:479-487.

van der Lubbe N, Jansen PM, Salih M, Fenton RA, van den Meiracker AH, Danser AH, Zietse R, and Hoorn EJ. 2012. The phosphorylated sodium chloride cotransporter in urinary exosomes is superior to prostanin as a marker for aldosteronism. *Hypertension* 60:741-748.
Wang Y, Chen Y, Zhang Y, Wu S, Ma S, Hu S, Zhang L, Shao C, Li M, and Gao Y. 2008. Differential ConA-enriched urinary proteome in rat experimental glomerular diseases. Biochem Biophys Res Commun 371:385-390.

Wisniewski JR, Zougman A, Nagaraj N, and Mann M. 2009. Universal sample preparation method for proteome analysis. Nat Methods 6:359-362.

Wu T, Du Y, Han J, Singh S, Xie C, Guo Y, Zhou XJ, Ahn C, Saxena R, and Mohan C. 2013. Urinary angiostatin—a novel putative marker of renal pathology chronicity in lupus nephritis. Mol Cell Proteomics 12:1170-1179.

Wu Y, and Foreman RC. 1991. The molecular genetics of alpha 1 antitrypsin deficiency. Bioessays 13:163-169.

Zacchia M, and Capasso G. 2008. Parvalbumin: a key protein in early distal tubule NaCl reabsorption. Nephrol Dial Transplant 23:1109-1111.

Zhao M, Li M, Li X, Shao C, Yin J, and Gao Y. 2014. Dynamic changes of urinary proteins in a focal segmental glomerulosclerosis rat model. Proteome science 12:42.

Legends

Figure 1. Urine protein-to-creatinine ratios before and after anesthesia (n=6 each group). * indicates p<0.05.

Figure 2. Semi-quantitative western blot analysis of two proteins. A) Levels of urinary transferrin before and after pentobarbital sodium anesthesia. B) Levels of urinary alpha-1-antiproteinase before and after chloral hydrate anesthesia. C) Quantitation of the transferrin by western blot analysis from 3 independent biological replicates. D) Quantitation of the alpha-1-antiproteinase by western blot analysis from 3 independent biological replicates * indicates p<0.05.

Tables

Table 1. Changes in the urine proteome identified by LC-MS/MS with two anesthetics.

Table 2. Changed proteins with anesthesia which exist in human stable urinary proteome and their corresponding human orthologs.

Additional files

Additional file 1. Label-free quantitation data of proteins identified in both anesthesia. A) Label-free quantitation data of proteins identified in pentobarbital sodium group. B) Label-
free quantitation data of proteins identified in chloral hydrate group.
Table 1. Changes in the urine proteome identified by LC-MS/MS with two anesthetics.

| Accession | Description                                      | P value | Pentobarbital sodium group fold change | Chloral hydrate group fold change | Candidate biomarkers |
|-----------|--------------------------------------------------|---------|---------------------------------------|----------------------------------|---------------------|
|           |                                                  |         | Rat 1   | Rat 2   | Rat 3   | Rat 7 | Rat 8 | Rat 9 |                       |                     |
| P17475    | Alpha-1-antiproteinase                            | 0.034   | 6.1↑    | 5.6↑    | 8.5↑    | 3.4↑  | 8↑   | 3.3↑  | Yes                    |                     |
| P07154    | Cathepsin L1                                      | 0.003   | 2.4↓    | 3.2↓    | 4↓      | 2.4↓  | 2↓   | 8.9↓  | Yes                    |                     |
| P07522    | Pro-epidermal growth factor                       | 0.001   | 2.5↓    | 2.8↓    | 3.4↓    | 5.4↓  | 3.3↓  | 2.1↓  | Yes                    |                     |
| P00758    | Kallikrein-1                                      | 0.002   | 2.1↓    | 3.3↓    | 3.3↓    | 7.5↓  | 2.7↓ | 2↓    | No                     |                     |
| Q5XI43    | Matrix-remodeling-associated protein 8            | 0.006   | 2.8↓    | 3.1↓    | 2.6↓    | 9.3↓  | 5.3↓ | 2.8↓  | No                     |                     |
| P15083    | Polymeric immunoglobulin receptor                 | 0.020   | 2.6↓    | 2.3↓    | 2.2↓    | 3↓    | 2.7↓ | 2.8↓  | No                     |                     |
| P27590    | Uromodulin                                       | 0.006   | 3↓      | 5.2↓    | 7↓      | 3.7↓  | 2↓   | 2.2↓  | Yes                    |                     |
| P02770    | Serum albumin                                     | 0.042   | 5.5↑    | 3.1↑    | 5.4↑    | —     | —    | —    | —                      | Yes                  |
| P12346    | Serotransferrin                                   | 0.049   | 6.8↑    | 2.1↑    | 4.3↑    | —     | —    | —    | —                      | Yes                  |
| P32038    | Complement factor D                              | 0.046   | 2.2↑    | 2.4↑    | 3.9↑    | —     | —    | —    | —                      | No                   |
| P10959    | Carboxylesterase 1C                              | 0.034   | 3.5↑    | 3.9↑    | 4.6↑    | —     | —    | —    | —                      | No                   |
| P20761    | Ig gamma-2B chain C region                        | 0.030   | 7.2↑    | 3.3↑    | 9.1↑    | —     | —    | —    | —                      | No                   |
| P50123    | Glutamyl aminopeptidase                           | 0.044   | 2.1↓    | 2.5↓    | 2.1↓    | —     | —    | —    | —                      | No                   |
| Q62867    | Gamma-glutamyl hydrolase                          | 0.046   | 2.2↓    | 3↓      | 3.3↓    | —     | —    | —    | —                      | Yes                  |
| P15684    | Aminopeptidase N                                 | 0.039   | 2.4↓    | 4.4↓    | 5.7↓    | —     | —    | —    | —                      | Yes                  |
| P26051    | CD44 antigen                                      | 0.006   | 2.9↓    | 2.5↓    | 2.6↓    | —     | —    | —    | —                      | No                   |
| P36373    | Glandular kallikrein-7, submandibular/renal       | 0.021   | 2.1↓    | 2.2↓    | 3.5↓    | —     | —    | —    | —                      | Yes                  |
| P98158    | Low-density lipoprotein receptor-related protein 2| 0.004   | 2.1↓    | 3.6↓    | 2.1↓    | —     | —    | —    | —                      | No                   |
| Q64230    | Meprin A subunit alpha                            | 0.000   | 2.7↓    | 3.6↓    | 3.4↓    | —     | —    | —    | —                      | Yes                  |
| P28826    | Meprin A subunit beta                             | 0.031   | 3.5↓    | 4.9↓    | 10.9↓   | —     | —    | —    | —                      | No                   |
| Accession | Description                                           | Fold Change | Activity | Regulator | Activity | Activity |
|-----------|-------------------------------------------------------|-------------|----------|-----------|----------|----------|
| Q64319    | Neutral and basic amino acid transport protein rBAT   | 0.014       | 2.5↓     | 2.7↓      | 4.5↓     | ——       | Yes      |
| P29598    | Urokinase-type plasminogen activator                  | 0.048       | 2.5↓     | 2.2↓      | 2.7↓     | ——       | No       |
| Q6DGG1    | Alpha/beta hydrolase domain-containing protein 14B    | 0.004       | ——       | 3.4↑      | 8↑       | 3.3↑     | No       |
| Q6IRK9    | Carboxypeptidase Q                                    | 0.037       | ——       | 2.9↑      | 3.6↑     | 4.8↑     | No       |
| P08649    | Complement C4                                        | 0.028       | ——       | 11.2↑     | 3.1↑     | 14↑      | No       |
| P61972    | Nuclear transport factor 2                            | 0.026       | ——       | 3.1↑      | 3.1↑     | 6.5↑     | No       |
| P02625    | Parvalbumin alpha                                     | 0.047       | ——       | 5.9↑      | 5↑       | 12.5↑    | Yes      |
| Q920A6    | Retinoid-inducible serine carboxypeptidase             | 0.019       | ——       | 4.2↑      | 4.2↑     | 4.7↑     | No       |
| P82450    | Sialate O-acetyltransferase                           | 0.016       | ——       | 5↑        | 9.4↑     | 2.4↑     | No       |
| P07632    | Superoxide dismutase [Cu-Zn]                          | 0.019       | ——       | 2.6↑      | 4.9↑     | 3.1↑     | Yes      |
| P02650    | Apolipoprotein E                                      | 0.032       | ——       | 2↓        | 5.2↓     | 3.3↓     | No       |
| Q9R0T4    | Cadherin-1                                            | 0.039       | ——       | 2.7↓      | 3.5↓     | 2.1↓     | Yes      |
| P31211    | Corticosteroid binding globulin                       | 0.038       | ——       | 3.6↓      | 2.1↓     | 2.8↓     | No       |
| Q9JJ40    | Na(+)/H(+) exchange regulatory cofactor NHE-RF3       | 0.047       | ——       | 3.0↓      | 2.7↓     | 3.2↓     | Yes      |
| P08460    | Nidogen-1 (Fragment)                                  | 0.020       | ——       | 4↓        | 2.5↓     | 4.1↓     | No       |
| Q63083    | Nucleobindin-1                                        | 0.043       | ——       | 16.7↓     | 10.8↓    | 3.7↓     | No       |
| P83121    | Urinary protein 3                                     | 0.033       | ——       | 2.2↓      | 3.3↓     | 2.1↓     | No       |
| P05371    | Clusterin                                             | 0.040       | ——       | 5.7↓      | 5.8↓     | 2.2↓     | No       |
Table 2. Changed proteins with anesthesia which exist in human core urinary proteome and their corresponding human orthologs.

| Group         | Uniprot (rat) | Human Gene ID | Uniprot (human) | Protein Name                          | Related-Disease                                           |
|---------------|---------------|---------------|-----------------|---------------------------------------|----------------------------------------------------------|
| both group    | P27590        | ENSG000000169344 | P07911          | Uromodulin                            | Fanconi Syndrome(Cutillas et al. 2004)                  |
|               | P00758        | ENSG000000167748 | P06870          | Kallikrein-1                          | None                                                     |
| pentobarbital sodium group | Q64319        | ENSG000000091513 | P02787          | Serotransferrin                       | Diabetic Nephropathy(Narita et al. 2004)                |
|               | Q628 67       | ENSG000000163631 | P02768          | Serum albumin                         | Nephrotoxicity(Nordberg et al. 2005)                    |
|               | P12346        | ENSG00000137563 | Q92820          | Gamma-glutamyl hydrolase              | Uranium Nephrotoxicity(Malard et al. 2009)              |
|               | P02770        | ENSG00000138079 | Q07837          | Neutral and basic amino acid transport protein rBAT | Sodium Loading(Thongboonkerd et al. 2003) |
| chloral hydrate group | P07632        | ENSG000000142168 | P00441          | Superoxide dismutase [Cu-Zn]          | Nephritis(Curtis et al. 1989)                           |
|               | Q6IRK9        | ENSG000000104324 | Q9Y646          | Putative uncharacterized protein      | None                                                     |
|               | P02625        | ENSG000000100362 | P20472          | Parvalbumin alpha                     | Skeletal Muscle Toxicity(Dare et al. 2002)              |
|               | P31211        | ENSG000000170099 | P08185          | Corticosteroid-binding globulin       | None                                                     |
|               | Q9R0T4        | ENSG000000039068 | P12830          | E-cadherin                            | Diabetic Nephropathy(Jiang et al. 2009)                 |
|               | Q6DGG1        | ENSG000000114779 | Q96IU4          | Alpha/beta hydrolase domain-containing protein 14B | None                                                     |
|               | Q920A6        | ENSG000000121064 | Q9HB40          | Retinoid-inducible serine carboxypeptidase | None                                                     |
|               | P02650        | ENSG000000130203 | P02649          | Apolipoprotein E                      | Bladder Cancer(Linden et al. 2012)                      |
|               | Q9JJ40        | ENSG000000174827 | Q5T2W1          | Na(+)/H(+) exchange regulatory cofactor NHE-RF3 | Aldosteronism(van der Lubbe et al. 2012)               |
|               | Q63083        | ENSG000000104805 | Q02818          | Nucleobindin-1                        | None                                                     |
Figure 1.
Figure 2.